U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07500298) titled 'Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer' on March 24.
Brief Summary: To learn if SAR445877 in combination with FOLFOX6 and bevacizumab can be safely given to patients with advanced MSS CRC.
Study Start Date: Sept. 03, 2026
Study Type: INTERVENTIONAL
Condition:
Phase 1
SAR445877
FOlfox6
Bevacizimab
First Line Treatment
Metastatic Colorectal Cancer (CRC)
Microsatellite Stable
Intervention:
DRUG: SAR445877
Given by IV
DRUG: FOLFOX6
Given by IV
DRUG: Bevacizumab
Given by IV
Recruitment Status: NOT_YET_RECRUITING
Sp...